Kalveer Flora, MPharm, London North West University Healthcare National Health Service (NHS) Trust, discusses how the NHS has overcome hurdles related to switching to biosimilars.
Transcript
I think, specific hurdles, and I think we hear this a lot: “Are the biosimilars safe? Are they effective? Are there any side effects?” Having gone through the switches, at each stage, we collected data to show that the biosimilars were just as safe, just as efficacious, worked just as well as the originators.
This mound of evidence helped build confidence at each transition. So our clinicians, our nurses, our pharmacists, our physiotherapists, all of our multidisciplinary team could see that, because we had this wealth of experience, at each stage, they became more confident. So now our consultants wouldn’t even think about having a problem with switching, whereas, in the beginning, we had problems with, “Oh, do they work? What happens if a patient feels that their condition has deteriorated once on it?”
I think, having gone through the process 4 times now, this has helped to build confidence at each level, and now it’s more of a routine thing rather than a new thing.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.